The London School of Hygiene & Tropical Medicine is to lead a major new clinical trial in Southern and East Africa which aims to tackle the high number of deaths caused by HIV-associated cryptococcal meningitis (CM), a severe fungal infection of the brain that occurs in patients with advanced HIV infection.
AMBITION hopes to identify a new very clinically-effective and cost-effective treatment for CM using very high single doses of the drug Liposomal Amphotericin B (Ambisome). The project will recruit 850 patients across six African sites, making it the largest ever CM trial. Recruitment will commence in late 2017.
Dr. Joe Jarvis
Joe Jarvis, Associate Professor from the London School of Hygiene & Tropical Medicine and Research Associate at the Botswana Harvard AIDS Institute Partnership is AMBITION’s Chief Investigator. He said: “Cryptococcal meningitis is a leading cause of death in HIV-infected individuals in Africa. Current drugs used to treat it are either ineffective or cost too much to administer. There is an urgent need to find novel treatments that can be safely given in low resource settings where the majority of cryptococcal meningitis cases occur. Being able to effectively treat this severe infection with a single high dose of liposomal amphotericin would revolutionise the management of late stage HIV-infection in Africa, and has the potential to save many thousands of lives every year.” Read more . . .
Q&A with Dr Joseph Makhema
The Botswana Harvard AIDS Institute Partnership (BHP) was established 20 years ago to help combat HIV/AIDS at the epicenter of the epidemic. At the time, about 37% of pregnant women in Botswana were infected with HIV. Dr Joseph Makhema was a young physician working what seemed like unending hours at the public hospital in Gaborone, where effective treatment was not yet available. Today, Dr Makhema is the CEO of the Institute he played an important role in establishing. Martha Henry, Executive Director of the Harvard AIDS Initiative, spoke with him about the BHP’s history and future. Continue reading
Author: Bakang Mhaladi
Date : Dec 05 Mon, 2016
GABORONE – AS the world marks World AIDS Day, Botswana has been unrelenting in its fight against the pandemic, with the launch of a ground-breaking HIV study targeting women this week.
Author: Gofaone Koogotsitse
Date : Dec 02 Fri, 2016
Botswana Harvard Aids Institute Partnership (BHP) on Tuesday officially launched an Antibody Mediated Prevention (AMP) Study with the idea of giving people antibodies that fight HIV to see if they will protect them from HIV infection.
Author Baboki Kayawe
Date : Nov 30 Wed, 2016
The Botswana Harvard AIDS Institute Partnership (BHP) yesterday launched its inaugural clinical study to look into the effectiveness of antibodies in reducing the acquisition of HIV among high-risk female populations.The research explores a new idea for HIV prevention, investigators explained on Tuesday.
Author: Tshepo Maphanyane
Date : June 10 2016
They live in our midst yet maintain a mysterious, almost ethereal aura about them.
Their complicated work embodies strength, determination and resilience and takes years of unrelenting dedication to perfect.
They are amongst the most intelligent, hard-working beings on our planet – they are scientists.
Botswana have not produced many scientists of a note – the impressive Catherine Kegakilwe Koofhethile is an obvious exception. Continue reading
Current on-going research continues to be selected and implemented collaboratively with the Ministry of Health to ensure relevance to Botswana’s Public Health challenges. Following the new WHO treatment guidelines having recommended the Universal Test and Treat (UTT) strategy and the UNAIDS having set Country targets for 90% of all HIV infected people to know their HIV status; 90% of those diagnosed with HIV infection being on ART; 90% of all people on ART having undetectable HIV in their blood, to as the 90 – 90 – 90 targets by the year 2020: The ongoing Botswana Combination Prevention Project, BCPP also known as the “Ya Tsie” study offers opportunity for Botswana to develop tools and modalities, monitoring and evaluation systems, and capabilities of various healthcare operational systems. These opportunities to develop new systems both at community and health care facility level would strengthen existing HIV/AIDS management systems in the MASA Programme based on research outcomes of the study. The Board of Directors is committed to support the BHP in its participation in such relevant studies and in its mandate. Continue reading
The Botswana-Harvard AIDS Institute Partnership (BHP) this week (01-12-2015) joined the world in commemorating World AIDS day. We at BHP celebrate the remarkable progress made in the fight against HIV/AIDS since the first commemoration 27 years ago. Continue reading
Author : Mmoniemang Motsamai
Date : Feb 04 Tue, 2014
The Ministry of Health has introduced two new devices for infants’ Safe Male Circumcision (SMC).